KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Equity Average (2016 - 2026)

TherapeuticsMD filings provide 15 years of Equity Average readings, the most recent being $26.9 million for Q1 2026.

  • On a quarterly basis, Equity Average changed 0.48% to $26.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $26.9 million, a 0.48% change, with the full-year FY2025 number at $27.1 million, down 4.26% from a year prior.
  • Equity Average hit $26.9 million in Q1 2026 for TherapeuticsMD, down from $27.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $33.6 million in Q1 2023 to a low of -$117.1 million in Q1 2022.
  • Median Equity Average over the past 5 years was $27.2 million (2024), compared with a mean of $7.4 million.
  • Biggest five-year swings in Equity Average: plummeted 184.61% in 2022 and later surged 536.77% in 2023.
  • TherapeuticsMD's Equity Average stood at -$6.6 million in 2022, then surged by 536.77% to $28.7 million in 2023, then fell by 5.01% to $27.2 million in 2024, then fell by 0.26% to $27.2 million in 2025, then dropped by 0.87% to $26.9 million in 2026.
  • The last three reported values for Equity Average were $26.9 million (Q1 2026), $27.2 million (Q4 2025), and $27.4 million (Q3 2025) per Business Quant data.